Product Details

Uniprot No.

Target Names

Alternative Names

CCR9; GPR28; C-C chemokine receptor type 9; C-C CKR-9; CC-CKR-9; CCR-9; G-protein coupled receptor 28; GPR-9-6; CD antigen CDw199

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human CCR9

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

4G2

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IF

Recommended Dilution

Application	Recommended Dilution
IF	1:20-1:200

Protocols

ELISA Protocol
Immunofluorescence (IF) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

CCR9, also known as C-C chemokine receptor type 9, plays a critical role in directing immune cell trafficking, particularly the migration of T lymphocytes and IgA-secreting plasma cells to the gut mucosa. This G-protein coupled receptor responds to the chemokine CCL25 and has become an important target for researchers investigating mucosal immunity, inflammatory bowel disease, and the gut-associated lymphoid tissue. Understanding CCR9-mediated signaling pathways offers valuable insights into both normal immune surveillance and pathological conditions affecting the gastrointestinal tract.

This recombinant monoclonal antibody, clone 4G2, provides the consistency and reliability that demanding immunology research requires. Generated against a synthetic peptide derived from human CCR9 and produced using recombinant technology, this antibody offers sequence-defined specificity with exceptional lot-to-lot reproducibility. Researchers can confidently integrate this reagent into long-term studies knowing that performance characteristics remain stable across different antibody lots.

The antibody has been validated across multiple experimental platforms, offering flexibility for diverse research workflows. Western blotting applications support dilutions from 1:500 to 1:5000, while immunofluorescence studies can be performed at 1:20 to 1:200. Immunoprecipitation protocols have been optimized at 1:200 to 1:1000. Functional ELISA testing demonstrates robust binding activity, with EC50 values ranging from 505.2 to 1494 ng/mL when tested against immobilized human CCR9. Immunofluorescence validation in HepG2 cells confirms reliable cellular localization detection, providing researchers with confidence when examining CCR9 expression patterns.

With cross-species reactivity to both human and mouse samples, this antibody serves as a versatile tool for translational immunology research exploring chemokine receptor biology and mucosal immune responses.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Target Background

Function

Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level.; (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.

Gene References into Functions

There were significantly increased CCR9 protein levels in failing human hearts. PMID: 27146447
this study showed that CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients. PMID: 26616645
Results indicated that the expression levels of CCR9 in lesional skin may be a useful biologic marker of the clinical efficacy of infliximab therapy in psoriasis patients. PMID: 26507968
Xray crystal structure of the CCR9 receptor in complex with vercirnon at 2.8 A resolution PMID: 27926729
It plays a pathogenic role in liver diseases and it will be a therapeutic target of the diseases. PMID: 27795503
that CCL25/CCR9 signal may provide cancer cells with chemotactic abilities through influencing several epithelial-mesenchymal transitionmarkers PMID: 27008282
Studies indicate important roles played by chemokine ligand 25 (CCL25)/chemokine receptor 9 (CCR9) in tumorigenesis, tumor chemoresistance and metastasis. PMID: 26879872
CCR9 and Integrin-beta7 expression has a differential effect on graft fate during acute graft-versus-host disease (GVHD) of the liver depending on the GVHD target tissue. PMID: 26348893
CCR9 mRNA and protein levels were significantly increased in the nasopharyngeal carcinoma group compared with the control group. PMID: 26279399
CCR9-CCL25 interaction promoted proliferation and suppressed apoptosis of non-small cell lung cancer cells by activating the PI3K/Akt pathway. PMID: 25691296
CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma. PMID: 26168791
We also show that primary tumors can be modeled in immunocompetent mice by microinjecting CCR9-expressing cancer cell lines into early-stage mouse blastocysts, which induces central immune tolerance PMID: 26006007
High CCR9 expression is associated with the pathogenesis of ulcerative colitis. PMID: 24936795
Expression of CCR9 and CCL25, the only natural ligand of CCR9, was significantly higher (p<0.0001) in NSCLC tissues and serum respectively, compared to their respective controls. PMID: 25296976
activation of Notch1 has a dominant-negative effect on Ccr9 transcription and that Notch1 and E proteins control the dynamic expression of Ccr9 during T cell development. PMID: 25710912
The results show the potential of the 91R monoclonal antibody as a therapeutic agent for treatment of CCR9-expressing tumors. PMID: 24870448
results suggest that CCR9 can act as a novel prognostic marker and therapeutic target for hepatocellular carcinoma PMID: 24481516
CCR9 expression is elevated in the nodal lymphomas of patients with GI involvement PMID: 24828696
Only rotavirus specific CD4 T cells expressed intestinal homing receptors alpha4beta7 and CCR9. PMID: 24606696
Data suggest that P-glycoprotein associate with the F-actin cytoskeleton through ezrin/radixin/moesin (ERM) in CCR9/CCL25 induced multidrug resistance of acute T-lymphocytic leukemia (T-ALL) cells. PMID: 23326330
Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. PMID: 21984373
We provide the first evidence that CCR9 and its natural ligand CCL25 are highly expressed by ovarian cancer tissue and their expression correlates with histological subtypes. PMID: 21637913
CCL25 enhanced the expression of MMP-1, -9, -11 and -13 active proteins by BrCa cells in a CCR9-dependent fashion. PMID: 21344163
CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system PMID: 21511186
The high fraction of circulating IgA+ and IgG+ B cells expressing CCR9 and CCR10 in the first months of life indicates activation of naive B cells in the gut, coinciding with bacterial colonization. PMID: 21075690
TLR2 ligands induce CCR9 and CCR10 expression by circulating B-cells and increase their chemotaxis. TLR2 stimulation also induced J chain and IgA production demonstrating the induction of mucosal-like antibody secreting cells. PMID: 20947433
CCR9 expression by monocytes is increased in rheumatoid arthritis PMID: 20738854
Results demonstrate enhanced pancreatic intraepithelial neoplasia and pancreatic cancer cell proliferation with activation of CCR9 by its selective ligand CCL25 PMID: 19756884
Studies indicate that D6 chemokine receptor(CCR-9) may act as scavenging decoys and are involved in clearance of chemokines. PMID: 20036838
more active homing of CCR9-926AG T cells to Peyer's patches may produce changes in Ag presentation and result in increased incidence of skin graft vs. host disease. PMID: 19525985
over-expressed TECK interacts with CCR9 on the endometrial stromal cells in the endometriotic milieu, which may contribute to the onset and progression of endometriosis. PMID: 20081876
A subset of CCR9+ T cells from normal donors has characteristics of mucosal T cells in terms of activated phenotype, proliferative response to anti-CD2 stimulation, a Th1 or Tr1 cytokine profile, and support for Ig production by cocultured B cells. PMID: 12816994
CCR9 selectively induced T-ALL CD4+ T-cell chemotaxis and adhesion. PMID: 14559839
High Expression of CCR9 is associated with prostate cancer cell migration and invasion PMID: 15623660
involved in the pathogenesis of lymphatic filarial disease PMID: 15717282
CCR9 overexpression is associated with Adult T-cell leukemia cells infiltrating gastrointestinal tract PMID: 17205512
CCR9 expression is reduced on epithelial and lamina propria T cells in untreated celiac disease. Down-regulation of CCR9 persists in intraepithelial T cells from well-treated patients. Possible ongoing immune activation preferentially within epithelium. PMID: 17570212
CCR9 is expressed on human melanoma cells and participates in the enhanced motility of melanoma cells and is likely a "homing receptor" for melanoma to the small bowel. PMID: 18245518
Functionally active CCR9 on melanoma cells facilitates metastasis to the small intestine which may explain high incidence of metastis to the small intestine. PMID: 18245522

Hide All

Subcellular Location

Cell membrane; Multi-pass membrane protein.

Protein Families

G-protein coupled receptor 1 family

Tissue Specificity

Highly expressed in the thymus and low in lymph nodes and spleen.

Database Links

HGNC: 1610

OMIM: 604738

KEGG: hsa:10803

STRING: 9606.ENSP00000350256

UniGene: Hs.225946

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA004848A0HU
Size	US$210
	Order now
Image	Immunofluorescence staining of HepG2 cells with CSB-RA004848A0HU at 1:33, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L). The Binding Activity of CCR9 with Anti-CCR9 recombinant antibody Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CCR9 at 2 μg/mL can bind Anti-CCR9 recombinant antibody (CSB-RA004848A0HU). The EC50 is 505.2-1494 ng/mL
Have Questions?	Leave a Message or Start an on-line Chat

CCR9 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background